Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by CEimpact. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CEimpact or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

What Should Pharmacists Know about Low-Dose Naltrexone?

33:21
 
Share
 

Manage episode 502333532 series 2931422
Content provided by CEimpact. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CEimpact or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Low-dose naltrexone (LDN) is generating growing interest as a potential therapy for conditions such as chronic pain and immune-related disorders. This episode offers a foundational overview of what LDN is, how it’s thought to work, where current evidence stands, and how pharmacists may encounter it in practice. Learn what pharmacists need to know to confidently approach patient questions about LDN and how it fits into current conversations in pharmacy and patient care.
HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact
GUEST
Michelle Moser, RPh
Retired Compounding Pharmacist

Joshua Davis Kinsey has no relevant financial relationships to disclose.

Michelle Moser was a volunteer board member for LDN Research Trust (ended June 2025), a board member for Alliance for Pharmacy Compounding (ended September 2024), and an employee of Revelation Pharma (ended June 2024). All relevant financial relationships have been mitigated.
Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Define low-dose naltrexone (LDN) and describe how it differs from traditional naltrexone dosing.
2. Identify proposed mechanisms of action and areas of emerging interest related to LDN use in practice.
0.05 CEU/0.5 Hr
UAN: 0107-0000-25-275-H01-P
Initial release date: 8/25/2025
Expiration date: 8/25/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

  continue reading

Chapters

1. Introduction to Low-Dose Naltrexone (00:00:00)

2. How LDN Works: Mechanism of Action (00:04:52)

3. Clinical Applications for Autoimmune Conditions (00:08:17)

4. Finding the Patient's "Sweet Spot" (00:14:36)

5. The Importance of Proper Compounding (00:19:19)

6. Monitoring Thyroid Function With LDN (00:24:33)

7. Resources and Hope for Patients (00:28:31)

351 episodes

Artwork
iconShare
 
Manage episode 502333532 series 2931422
Content provided by CEimpact. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CEimpact or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Low-dose naltrexone (LDN) is generating growing interest as a potential therapy for conditions such as chronic pain and immune-related disorders. This episode offers a foundational overview of what LDN is, how it’s thought to work, where current evidence stands, and how pharmacists may encounter it in practice. Learn what pharmacists need to know to confidently approach patient questions about LDN and how it fits into current conversations in pharmacy and patient care.
HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact
GUEST
Michelle Moser, RPh
Retired Compounding Pharmacist

Joshua Davis Kinsey has no relevant financial relationships to disclose.

Michelle Moser was a volunteer board member for LDN Research Trust (ended June 2025), a board member for Alliance for Pharmacy Compounding (ended September 2024), and an employee of Revelation Pharma (ended June 2024). All relevant financial relationships have been mitigated.
Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Define low-dose naltrexone (LDN) and describe how it differs from traditional naltrexone dosing.
2. Identify proposed mechanisms of action and areas of emerging interest related to LDN use in practice.
0.05 CEU/0.5 Hr
UAN: 0107-0000-25-275-H01-P
Initial release date: 8/25/2025
Expiration date: 8/25/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

  continue reading

Chapters

1. Introduction to Low-Dose Naltrexone (00:00:00)

2. How LDN Works: Mechanism of Action (00:04:52)

3. Clinical Applications for Autoimmune Conditions (00:08:17)

4. Finding the Patient's "Sweet Spot" (00:14:36)

5. The Importance of Proper Compounding (00:19:19)

6. Monitoring Thyroid Function With LDN (00:24:33)

7. Resources and Hope for Patients (00:28:31)

351 episodes

Semua episode

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play